anti-CD19 CAR T-cell therapy (Beijing Doing Biomedical)

N/A

Report date: 2025/06/11 10:58:51

Base Information

Drug Nameanti-CD19 CAR T-cell therapy (Beijing Doing Biomedical)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsB-lymphocyte antigen CD19 modulatorsT lymphocytes stimulants
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Doing Biomedical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Doing Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A